price and market share gains
have kept revs flat. We expect the launch of
Plegridy
(approved in EU today and US expected in 2H) to
accelerate share gains which should ... Case
long-acting agents and a lower discount on pipeline assets. We daclizumab and
Plegridy
as
$502
assume: underappreciated assets that can move
1) -$7.78 in global Teclidera sales ... 2012A 2013A 2014E 2015E 2016E 2017E 2018E 2019E 2020E
1014A 2014A 3014E 4014E
Avonex)